Why is Fosun Pharma privatizing Henlius at this time? | Jianzhi Research

The suspension of Henlius stocks has finally been resolved, consistent with previous market rumors: Fosun Pharma will privatize Henlius for delisting, with a privatization valuation of approximately RMB 12.4 billion. Fosun Pharma's bid for each share of Henlius is HKD 24.60, a premium of 30.6% over its pre-suspension closing price. Based on last year's net profit of CNY 546 million for Henlius, this privatization has a PE ratio of approximately 23 times. The total transaction is HKD 5.4 billion, which will use no more than HKD 3.7 billion in acquisition loans. Henlius has a total share capital of 543.5 million shares, including 163.4 million H shares and 380.1 million non-listed shares. The tenderer in this case is Fosun.

wallstreetcnJun 25 03:26 ET

There is a differentiation in the small and large-cap style, with the Shanghai-Shenzhen 300 ETF rising and the CSI Midcap 200 Index ETF and China Securities 2000 Index ETF falling this year.

Delisted Yuan Cheng, Delisted Carbon Element, and Delisted Tongda, these three delisted stocks were all collectively resumed trading today, and the stock prices fell sharply. Delisted Yuan Cheng's decline reached 96%, Delisted Carbon Element's declined 83%, and Delisted Tongda's declined 80%. These three companies were all terminated from stock listing by the Shanghai Stock Exchange due to financial problems on May 28th. Last night, all three delisted stocks issued announcements stating that the start date of the delisting arrangement period for their stocks will be June 5th, 2024, and the expected date of the last transaction will be June 26th, 2024. Within five trading days after the expiration of the delisting arrangement period, the exchange will delist the company's stocks.

Gelonghui FinanceJun 5 05:05 ET

Maxeon Solar Technologies' Largest Shareholder TCL Zhonghuan Renewable Energy Technology to Invest $97.5M Via a Debt Investment and an Additional $100M Equity Investment

BenzingaMay 30 09:18 ET

Report: Fosun Pharmaceuticals Considers Privatizing Hong Kong Stock Holding Subsidiary Fu Hong Han Lin

On Monday, according to media reports quoting people familiar with the matter, Fosun Pharmaceutical is considering a privatization acquisition of Fuhong Hanlin, which is listed on the Hong Kong stock market. People familiar with the matter said that Fosun Pharmaceuticals is cooperating with a consulting agency on a potential privatization offer plan, and other investors may also join the deal. Fuhong Hanlin is a holding subsidiary of Fosun Pharmaceutical. Fosun Pharmaceutical holds 53.61% of Fuhong Hanlin's total share capital. Since May 23, Fu Hong Hanlin has suspended trading on the Hong Kong Stock Exchange pending the announcement of the merger and acquisition. Negotiations are still ongoing, and it remains to be seen whether a deal will actually be reached in the future.

wallstreetcnMay 29 09:12 ET

The Shanghai and Shenzhen Exchange announced that the IPOs of Goerwei and Ola shares were terminated

On the evening of May 27, the Shenzhen Stock Exchange and the Shanghai Stock Exchange respectively terminated the IPO reviews of Goerwei and Ola shares.

wallstreetcnMay 27 18:44 ET

Circuit Hyper | Future Intelligent Business Exploration: Individual AI Assistants Equal Rights

GAI's affirmative future commercial value thinking.

wallstreetcnMay 17 06:02 ET